Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corp (LFVN) delivers science-driven health solutions through nutrigenomic research and dietary supplements. This news hub provides investors and stakeholders with essential updates on corporate developments, product innovations, and market positioning in the nutraceutical industry.
Access timely regulatory filings, earnings reports, and press releases alongside analysis of scientific advancements. Our curated collection includes updates on weight management systems, cognitive enhancement products, and dermatological solutions backed by gene expression research.
Key content categories cover financial performance metrics, research partnerships, product launch details, and corporate governance updates. Bookmark this page for streamlined access to verified information supporting informed decisions about LFVN's market activities.
LifeVantage (Nasdaq:LFVN), a health and wellness company focused on cellular health products, has scheduled its third quarter fiscal year 2025 financial results announcement for May 6, 2025, after market close.
The company will host an investor conference call at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day. U.S. investors can participate by dialing (877) 704-4453, while international callers should use (201) 389-0920.
A replay will be available until May 20, 2025, accessible via (844) 512-2921 (U.S.) or (412) 317-6671 (international) using confirmation code 13752773. A live webcast will be simultaneously available on the company's Investor Relations website, with a 30-day archive period.
LifeVantage (LFVN) is expanding its MindBody GLP-1 System™ (MB System™) internationally following significant success in the U.S. market, where it contributed to a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024.
The MB System™ launched on March 15, 2025, in Japan for both Consultants and Customers, while becoming available exclusively to Consultants in Australia, New Zealand, Europe, UK, Mexico, and Thailand, with customer access starting April 25. The product is designed to naturally activate the body's GLP-1 production for metabolic health benefits.
The expansion targets the growing global GLP-1 pharmaceutical market, valued at $53.46 billion in 2024 and projected to reach $156.71 billion by 2030 with a 17.5% CAGR. LifeVantage plans to launch the MB System™ in the Philippines and Taiwan in early summer, followed by Canada later in the year.
LifeVantage (LFVN) has announced the expansion of its LV360 initiative and Evolve Compensation Plan into the Philippines, Taiwan, Hong Kong, and Singapore markets, effective March 1, 2025. This marks Phase 3 of the global rollout, following successful launches in Canada, Mexico, and Europe in February 2024, and in the US, Australia, New Zealand, and Japan in March 2023.
The Evolve Compensation Plan is structured to provide multiple income streams for Consultants through business building and product sales initiatives. The plan features early income bonuses, performance rewards, and mentorship incentives, designed to support both product-focused entrepreneurs and team builders.
CEO Steve Fife emphasized that the LV360 transformation, initiated two years ago, has been important in adapting to current direct sales industry trends and empowering Consultants with essential tools for business growth.
LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced a quarterly dividend payment. The company's Board of Directors has approved a cash dividend of $0.04 per share of common stock. The dividend will be paid on March 17, 2025, to stockholders of record as of the close of business on March 3, 2025.
LifeVantage (LFVN) reported strong financial results for Q2 fiscal 2025, with revenue reaching $67.8 million, up 31.3% year-over-year. The company's performance was driven by the successful launch of MindBody GLP-1 System™ in October. Key highlights include:
- Americas revenue increased 46.3%, with US revenue up 48.8%
- Asia/Pacific & Europe revenue decreased 15.5%
- Net income per diluted share was $0.19, compared to a loss of $0.05 year ago
- Adjusted EBITDA reached $6.5 million vs $3.1 million last year
- Gross profit margin improved to 80.5%
The company raised its fiscal 2025 guidance, now expecting revenue between $235-245 million, adjusted EBITDA of $21-24 million, and adjusted EPS of $0.72-0.88. A quarterly dividend of $0.04 per share was declared, payable March 17, 2025.
LifeVantage (LFVN) has completed an international in vitro cell study on its MB System™, the international formulation of the MindBody GLP-1 System™. The study examined the formula's effects on GLP-1 hormone production in specialized L-cells found in the colon. The research analyzed key genes involved in GLP-1 production and regulation, including GCG, GLP1R, DPP-4, PYY, and PPY.
The study utilized ELISA and fluorescent microscopy to evaluate the two-product system's synergistic potential, which aims to enhance GLP-1 production through L-cell activation and gut microbiome optimization. The US version of the product, launched in October, showed positive results in a 12-week human clinical trial, demonstrating a 140% average increase in GLP-1 production. The international version is scheduled for launch in March.
LifeVantage (LFVN), a health and wellness company focusing on cellular health products, has announced it will release its second quarter fiscal 2025 financial results on February 5, 2025, after market close. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day.
Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 internationally. A replay will be available until February 19, 2025, accessible by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13750382. A simultaneous webcast will be available on the company's Investor Relations website, with a 30-day archive period.
LifeVantage (Nasdaq: LFVN) has received silver recognition for its TrueScience® Activated Skincare Collection in the Most Innovative Product Line category at the Best in Biz Awards 2024. The collection combines science-backed ingredients with clean beauty standards, featuring notable products like TrueRenew Daily Firming Complex and TrueHydrate Brightening Moisturizer.
The skincare line has achieved remarkable success, driving a 43% revenue increase in its first month following the 2023 launch. The products maintain high clean beauty standards with Think Dirty® scores of 0 or 1, demonstrating the company's commitment to ingredient safety and effectiveness. According to CEO Steve Fife, this recognition validates LifeVantage's mission to combine activation science with clean formulations working at the cellular level.
The Best in Biz Awards, judged by editors and reporters from leading North American publications, recognizes excellence and innovation across industries.
LifeVantage (Nasdaq: LFVN) has appointed Todd Thompson as Chief Information and Innovation Officer. Thompson brings extensive experience in technology leadership, having served as Chief Information Officer at prominent companies including JetBlue Airways, Starwood Hotels, Vivint, and dōTERRA. His expertise includes scaling operations, improving back-end systems, and delivering customer-facing technologies.
CEO Steve Fife emphasized that Thompson's appointment aligns with LifeVantage's growth strategy and their goal to enhance digital experiences for independent Consultants and customers. Thompson's previous roles also include consulting positions at SBI.Razorfish, Arthur Andersen Business Consulting, and Andersen Consulting, as well as IT leadership positions at Nu Skin.
LifeVantage (LFVN) hosted its annual Global Kickoff on January 11, 2025, announcing its vision for 2025 under the theme 'Drive ERA.' The company revealed plans for international expansion of its MindBody GLP-1 System™ and the Evolve Compensation Plan.
Key announcements include the global launch of MindBody GLP-1 System™ starting in Japan on March 15, 2025, followed by Australia, New Zealand, Mexico, Europe, and Thailand, with full customer availability on April 24, 2025. The company also released new findings from a third-party cell study showing synergistic benefits between MindBody GLP-1 System™ and Protandim® Nrf2 Synergizer®, activating 22 new genes for enhanced organ health, antioxidant defense, and fat metabolism.
The Philippines, Taiwan, Hong Kong, and Singapore will transition to the Evolve Compensation Plan on March 1, with Thailand following by fiscal year-end. The company also introduced the Drive ERA Incentive program running from January to March 2025, and updated its Evolve Perks recognition program.
